(Q44924721)

7 December 2017

title

Helicobacter pylori eradication improves pre-existing reflux esophagitis in patients with duodenal ulcer disease (English)

1 reference

eradication of infectious diseases

7 December 2017

0 references

1 reference

1 reference

Kuniharu Ishiki

1

1 reference

7 December 2017

Motowo Mizuno

2

1 reference

7 December 2017

Susumu Take

3

1 reference

7 December 2017

Yasuhiro Nagahara

4

1 reference

7 December 2017

Tomowo Yoshida

5

1 reference

7 December 2017

Kazuhide Yamamoto

6

1 reference

7 December 2017

Hiroyuki Okada

7

1 reference

7 December 2017

Kenji Yokota

8

1 reference

7 December 2017

Keiji Oguma

9

1 reference

7 December 2017

Yasushi Shiratori

10

1 reference

7 December 2017

language of work or name

English

0 references

publication date

1 June 2004

1 reference

Clinical Gastroenterology and Hepatology

7 December 2017

published in

1 reference

7 December 2017

volume

2

1 reference

7 December 2017

issue

6

1 reference

7 December 2017

page(s)

474-479

1 reference

The bacteria behind ulcers.

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900165-X

7 January 2021

Review article: Helicobacter pylori and gastro-oesophageal reflux disease-clinical implications and management

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900165-X

7 January 2021

No protective role of Helicobacter pylori in the pathogenesis of reflux esophagitis in patients with duodenal or benign gastric ulcer in Korea

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900165-X

7 January 2021

Review article: gastro-oesophageal reflux disease and Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900165-X

7 January 2021

Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900165-X

7 January 2021

High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori: impacts of hiatal hernia and corpus gastritis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900165-X

7 January 2021

Is Helicobacter pylori eradication associated with gastroesophageal reflux disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900165-X

7 January 2021

Curing Helicobacter pylori infection in patients with duodenal ulcer does not provoke gastroesophageal reflux disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900165-X

7 January 2021

The association between CagA status and the development of esophagitis after the eradication of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900165-X

7 January 2021

Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900165-X

7 January 2021

Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900165-X

7 January 2021

Meta-analysis: the relationship between Helicobacter pylori infection and gastro-oesophageal reflux disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900165-X

7 January 2021

Improvement of reflux symptoms 3 years after cure of Helicobacter pylori infection: a case-controlled study in the Japanese population

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900165-X

7 January 2021

Impact of Helicobacter pylori eradication on heartburn in patients with gastric or duodenal ulcer disease -- results from a randomized trial programme

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900165-X

7 January 2021

Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900165-X

7 January 2021

The endoscopic assessment of esophagitis: a progress report on observer agreement.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900165-X

7 January 2021

Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900165-X

7 January 2021

Studies of 13C-urea breath test for diagnosis of Helicobacter pylori infection in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900165-X

7 January 2021

Helicobacter pylori in gastro-oesophageal reflux disease: causal agent, independent or protective factor?

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900165-X

7 January 2021

Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900165-X

7 January 2021

Effect of Helicobacter pylori products and recombinant cytokines on gastrin release from cultured canine G cells

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900165-X

7 January 2021

Prevalence of reflux esophagitis in patients with duodenal ulcer and gastric ulcer

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900165-X

7 January 2021

Changes in gastric acid secretion assayed by endoscopic gastrin test before and after Helicobacter pylori eradication

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900165-X

7 January 2021

Helicobacter pylori infection and chronic gastric acid hyposecretion

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900165-X

7 January 2021

Eradication of Helicobacter pylori increases gastric acidity in patients with atrophic gastritis of the corpus-evaluation of 24-h pH monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900165-X

7 January 2021

Interleukin 1 beta and tumour necrosis factor alpha inhibit acid secretion in cultured rabbit parietal cells by multiple pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900165-X

7 January 2021

Major virulence factors, VacA and CagA, are commonly positive in Helicobacter pylori isolates in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900165-X

7 January 2021

Structure of cag pathogenicity island in Japanese Helicobacter pylori isolates

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900165-X

7 January 2021

Determination of Helicobacter pylori virulence by simple gene analysis of the cag pathogenicity island

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900165-X

7 January 2021

Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900165-X

7 January 2021

Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900165-X

7 January 2021

The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900165-X

7 January 2021

10.1016/S1542-3565(04)00165-X

Identifiers

DOI

1 reference

7 December 2017

1 reference